1 to 10 of 226
Sort by

Library Entry
Immunotherapy for the Treatment of Lung Cancer

Published in partnership with the Society for Immunotherapy of Cancer (SITC), this Patient Resource Guide provides current, medically accurate information intended specifically for patients with Lung cancers and their caregivers. Immunotherapy for the Treatment of Lung cancer outlines...

2019 Immunotherapy Lung.pdf

Library Entry
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

While immune checkpoint inhibitors (ICIs) have had a major impact on the clinical outcome of several solid tumors, including non-small cell lung cancer, the potential role of ICIs is currently under investigation in SCLC and some promising data are available. The authors summarize the current...

Library Entry
Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy

Little is known about tumor-associated vasogenic edema in brain metastasis, yet it causes significant morbidity and mortality. The authors' purpose was to characterize edema in patients treated with anti-PD-1 and to study potential causes of vessel leakage in humans and in pre-clinical models....

Library Entry
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer

The authors profiled genomic and epigenomic data from a naïve Chinese non-small cell lung cancer (NSCLC) cohort and investigated the association between tumor mutation burden (TMB) and DNA methylation (DNAm) to explore potential alternative/complimentary biomarkers for NSCLC immunotherapies. The...

Library Entry
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the current dosing strategies. The authors' primary objectives were to...

Library Entry
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. The authors aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citrulline (marker of the intestinal barrier) on nivolumab efficacy in non-small...

Library Entry
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors

Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used marker, programmed death ligand 1 (PD-L1). The authors hypothesized that circulating tumor...

Library Entry
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Using mouse models, the authors studied the immunological profile of mutant EGFR-driven lung...